The development component of the UCSD CFAR is designed to facilitate and encourage new investigators and new ideas in HIV and AIDS research. The intent is to optimize opportunities for productive research by providing immediate financial support in association with resource support provided by the core facilities. Three categories of developmental grants will be supported although, the number and type of these categories are flexible. Presently, the three categories are: 1) Investigators new to AIDS research; 2) Feasibility studies and 3) Evolving research opportunities. Requests for submission of developmental grants will be advertised through the Administrative Core twice a year, for funding in January and June. The submissions are evaluated by a review committee which has an evolving membership. Additional members from related fields will be added as applications for developmental funds become increasingly diverse in scope. Merit is the driving criterion for making the awards; however, fostering the development of junior and minority investigators are two important programmatic goals which are also considered in the prioritization of awards. The amount of the awards given will be increased to $35,000. As part of their awards, investigators are required to provide documentation of publications and peer reviewed funding that results from the developmental awards. They are also required to cite CFAR support in publications which are generated or related to the research performed using CFAR developmental funds. With the growth of the CFAR, we anticipate a greater number of innovative and timely projects will be funded, attracting new members and affiliates who can advance HIV and AIDS research, supported, in part, by developmental funds.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI036214-08S1
Application #
6500684
Study Section
Project Start
2001-09-30
Project End
2002-05-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
$180,480
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Giamouridis, Dimosthenis; Gao, Mei Hua; Lai, N Chin et al. (2018) Effects of Urocortin 2 Versus Urocortin 3 Gene Transfer on Left Ventricular Function and Glucose Disposal. JACC Basic Transl Sci 3:249-264
Jenks, Jeffrey D; Reed, Sharon L; Seidel, Danila et al. (2018) Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents 52:706-712
Drumright, Lydia N; Weir, Sharon S; Frost, Simon D W (2018) The role of venues in structuring HIV, sexually transmitted infections, and risk networks among men who have sex with men. BMC Public Health 18:225
Francesconi, Walter; Berton, Fulvia; Marcondes, Maria Cecilia G (2018) HIV-1 Tat alters neuronal intrinsic excitability. BMC Res Notes 11:275
Lin, Timothy C; Gianella, Sara; Tenenbaum, Tara et al. (2018) A Simple Symptom Score for Acute Human Immunodeficiency Virus Infection in a San Diego Community-Based Screening Program. Clin Infect Dis 67:105-111
Saag, Michael S; Günthard, Huldrych F; Smith, Davey M (2018) Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment-Reply. JAMA 320:2154
Howe, Chanelle J; Dulin-Keita, Akilah; Cole, Stephen R et al. (2018) Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. Am J Epidemiol 187:316-325
Arredondo, J; Gaines, T; Manian, S et al. (2018) The law on the streets: Evaluating the impact of Mexico's drug decriminalization reform on drug possession arrests in Tijuana, Mexico. Int J Drug Policy 54:1-8
Hoenigl, Martin; Orasch, Thomas; Faserl, Klaus et al. (2018) Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis. J Infect :
Moore, David J; Jain, Sonia; Dubé, Michael P et al. (2018) Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Clin Infect Dis 66:1566-1572

Showing the most recent 10 out of 921 publications